Our mission is to identify and gain insights from the genetic and molecular pathways involved in atherosclerotic disease, and exploit these pathways to improve therapies with the aim of eradicating atherosclerotic diseases.

The Cardiovascular Immunotherapy Unit is dedicated to advancing the understanding and treatment of cardiovascular diseases through innovative immunotherapeutic strategies.

Our mission is to investigate the pathophysiological aspects of cardiovascular diseases and the development of tissue engineering solutions for regeneration.

Our mission is to repurpose existing drugs for next-generation cardiovascular disease therapy.

Our mission is to detect the earliest signs of heart and blood vessel damage with a view to preventing serious complications later in life.

Our mission is to reduce death and disability associated with heart and lower limb arterial disease by reducing atherosclerotic plaque build-up.

We turn research into tangible and sustainable change in community, in healthcare, and in public policy to improve the quality of life of Aboriginal people.

Our mission is to identify and explore the cellular changes that are unique to each individual’s cardiovascular disease, with the ultimate goal of personalised treatment.

Our focus is on understanding the differences between healthy heart enlargement and heart enlargement associated with disease.

Our mission is to detect silent atrial fibrillation in the population and treat it, to prevent as many strokes as possible.

Our mission is to determine the impact of inflammation on the structure and function of the arteries which have a key role in controlling blood pressure.

Our mission is to understand fundamental mechanisms in molecular and cellular biology and develop more effective treatments for the debilitating conditions associated with vascular complications.

Our mission is to understand the causes and progression of preeclampsia in pregnancy and examine the links between high blood pressure and cardiovascular disease in women.